Advertisement

Issue 19, Volume 128

Cover Figure: MOZ is essential for maintenance of adult hematopoietic stem cells. See the article by Sheikh et al.

WASHINGTON, November 10, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

The bulk of the hematopoietic stem cell population is dispensable for murine steady-state and stress hematopoiesis
In a plenary paper, Schoedel et al provide important evidence for the emerging view that hematopoiesis at steady state and during stress is largely driven from stages downstream from hematopoietic stem cells (HSCs); thus, HSCs are dispensable under those conditions.

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia
Speedy et al identify germ line loss-of-function mutations involving the telomere shelterin complex in familial chronic lymphocytic leukemia.

Aged neutrophils contribute to the first line of defense in the acute inflammatory response
Uhl et al provide evidence that aged neutrophils arrive at sites of inflammation before “young” neutrophils and dominate the inflammatory response in terms of numbers and efficiency of bacterial phagocytosis.

Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium
There are few data on the risks of thrombosis in pregnancy in women with hereditary thrombophilia. This study provides important information for counseling women about venous thrombosis prophylaxis during pregnancy.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan et al analyze in detail the incidence, clinical presentation, and outcomes of patients who develop late-onset acute graft-versus-host disease (GVHD).

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
The authors report the remarkable efficacy of a 3-drug regimen based on lenalidomide, cyclophosphamide, and prednisone in lenalidomide-refractory patients in a phase 1/2 trial after a median of 3 prior lines of therapy.

 

This week's complete table of contents

Why Submit to Blood?

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.